Compare GETY & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | AGEN |
|---|---|---|
| Founded | 1995 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 274.8M |
| IPO Year | 2022 | 1999 |
| Metric | GETY | AGEN |
|---|---|---|
| Price | $0.38 | $7.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.78 | ★ $14.50 |
| AVG Volume (30 Days) | 5.2M | ★ 8.2M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $926,244,000.00 | $42,877,086.00 |
| Revenue This Year | $0.37 | $107.63 |
| Revenue Next Year | $1.47 | N/A |
| P/E Ratio | ★ N/A | $6.50 |
| Revenue Growth | 0.82 | ★ 89.95 |
| 52 Week Low | $0.38 | $2.71 |
| 52 Week High | $3.21 | $8.70 |
| Indicator | GETY | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 27.88 | 74.52 |
| Support Level | N/A | $3.09 |
| Resistance Level | $0.93 | $8.70 |
| Average True Range (ATR) | 0.06 | 0.82 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 0.87 | 63.04 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.